<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802135</url>
  </required_header>
  <id_info>
    <org_study_id>2019-51</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04802135</nct_id>
  </id_info>
  <brief_title>Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electrical activity emerges in the third trimester of pregnancy, plays an important role in&#xD;
      the construction of cortical maps, and is impaired in patients with severe early epileptic&#xD;
      encephalopathies (EOEE). EOEE are rare and severe epileptic syndromes characterized by&#xD;
      epilepsy that begins within the first three months of life and is associated with rapid&#xD;
      deterioration of motor, cognitive and behavioral skills.&#xD;
&#xD;
      There is a genetic basis for the EOEE. Together with other laboratories, the investigators&#xD;
      have identified de novo pathogenic variants in the KCNQ2 gene encoding the Kv7.2 subunit of&#xD;
      the Kv7 / M potassium channel, a channel known to control neuronal excitability in the brain&#xD;
      and spinal cord. via the current M (IM). Pathogenic variants of the KCNQ2 gene represent the&#xD;
      main cause of EOEE and the term KCNQ2-related epileptic encephalopathy (KCNQ2-REE) is now&#xD;
      used to define this condition.&#xD;
&#xD;
      KCNQ2-REE patients have a remarkably homogeneous phenotype at the start, with epilepsy that&#xD;
      begins in the first days after birth, seizures that result in tonic muscle spasms that last&#xD;
      from 1 to 10 seconds, and an interictal EEG called &quot;suppression-burst&quot;. &quot;That is, paroxysmal&#xD;
      bursts of activity interspersed with periods of electrical silence. In this group, more than&#xD;
      50% of the patients present a remission of the epilepsy and a quasi-normalization of the EEG&#xD;
      which can occur a few weeks to several months after the onset of the seizures. Despite this&#xD;
      positive evolution in terms of seizures, the developmental progression is abnormal and the&#xD;
      phenotype is severe with an absence of language, autistic behavior and a subsequent&#xD;
      development of motor disorders such as diplegia, spasticity, ataxia or dystonia.&#xD;
&#xD;
      The ambition of this project is to increase knowledge of epileptic encephalopathies linked to&#xD;
      KCNQ2 at the clinical and molecular levels, to decipher the pathophysiological mechanisms and&#xD;
      to propose therapeutic strategies.&#xD;
&#xD;
      This project aims to better describe the clinical, EEG, imaging, developmental and long-term&#xD;
      follow-up characteristics of patients carrying the KCNQ2 mutation identified in the&#xD;
      laboratory.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2021</start_date>
  <completion_date type="Anticipated">March 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>importance of the developmental disorder</measure>
    <time_frame>Month 36</time_frame>
    <description>Developmental quotient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>definition of the active phase of epilepsy</measure>
    <time_frame>Month 36</time_frame>
    <description>Presence of at least monthly seizures and interictal EEG showing paroxysmal abnormalities</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Epileptic Encephalopathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey</intervention_name>
    <description>directive questionnaire administered during an individual face-to-face interview</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective observational study initially then prospective with inclusion of all patients&#xD;
        with a KCNQ2-REE whose diagnosis was made in the EPIGENE network&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epilepsy beginning before 1 month of life, and requiring the initiation of&#xD;
             anti-epileptic treatment&#xD;
&#xD;
          -  Without occasional cause&#xD;
&#xD;
          -  Without brain malformation explaining epilepsy&#xD;
&#xD;
          -  No opposition from parents / guardians&#xD;
&#xD;
          -  Possibility for parents to complete parent questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neonatal attacks of occasional cause (glycemic disorder, infection, etc.)&#xD;
&#xD;
          -  Acquired neonatal epilepsy (post-anoxic encephalopathy, stroke sequelae, etc.)&#xD;
&#xD;
          -  Neonatal epilepsy related to a brain malformation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Olivier Arnaud</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Milh</last_name>
    <phone>0491322903</phone>
    <phone_ext>33</phone_ext>
    <email>mathieu.milh@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Van Bogaert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel Pedespan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémie Lefranc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Nguyen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile Laroche</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetan Lesca</last_name>
    </contact>
    <investigator>
      <last_name>Dorthée Ville</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Milh</last_name>
      <phone>0491322903</phone>
      <phone_ext>33</phone_ext>
      <email>mathieu.milh@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agathe Roubertie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyril Mignot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Auvin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rima Nabbout</last_name>
      <email>rima.nabbout@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvia Napuri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne De Saint Martin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Cances</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Anne Barthez</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EOEE</keyword>
  <keyword>epilepsy</keyword>
  <keyword>KCNQ2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

